alexandeR

kharlamov

John

R.D.

M.D., FESC, FACC, FEACVI
 
Physician, Practicing Cardiologist | Trialist | Innovator | Translational Researcher |
Heart Health Advocate and Volunteer | Messenger
Pioneer of Cardiovascular Nanomedicine
Clinical Cardiology: Non-Invasive, Interventional, Acute and Intensive Care | 
Imaging (MSCT/ CCTA, CMR, MPI, PET, TTE, QCA, IVUS, OCT, NIRS) |
Translational Cardiology: Arterial Remodeling/ Atherosclerosis | Biomedical Engineering, Coronary Devices |
Preventive Cardiology and Genetics | Regenerative Medicine and Longevity | Nanomedicine |
Sex- and Gender-Based Medicine | Public Health Management and Advocacy | 
Philosophy of Science: Consciousness, Immortality, Singularitarianism, Transhumanism | 
Civilizational Anti-Russian Sentiment
 
*** 

Scio quia omnia potes, et nulla te latet cogitatio, Iob 42:2
Potestas et terror apud eum est, qui facit concordiam in sublimibus suis, Iob 25:2
Quia hæc dicit Excelsus, et Sublimis, habitans æternitatem, et sanctum nomen ejus, in excelso et in sancto habitans, et cum contrito et humili spiritu : ut vivificet spiritum humilium, et vivificet cor contritorum, Isaias 57:15
Ego dixi : Dii estis, et filii Excelsi omnes, Psalmi 82:6

3B97CCC3-EB26-4E1E-9BD0-5A36EA782F1C.JPE

ABOUT

ME!

  • LinkedIn Social Icon
  • Google Scholar
  • NCBI
  • Scopus
  • Publons
  • ORCiD

Dr. J. A. R. D. Kharlamov has 26 years of clinical experience in cardiology (since 1996; a Consultant Physician since 2007, a Board-Certified Cardiologist since 2010), 21 years of translational research in nanomedicine and biomedical engineering (since 2001), and about 15 years of the bench-to-bedside studies in interventional cardiology (a leader of the research group since 2007) including academic research in imaging, vascular biology, and pathology, RTD of cardiovascular imaging software (artificial intelligence/ machine learning), medical devices (bioresorbable scaffolds and stents, nanomedicine). He moved to Russia in babyhood, having American, Dutch, and British roots, and received his M.D. (Doctor of Medicine) cum laude in 2005 from Ural State Medical University (Yekaterinburg, Russia). After finishing his internship in internal medicine in 2007 at the Ural Institute of Cardiology (Yekaterinburg, Russia), he started as a physician and translational researcher (a team leader as an Assistant Professor) in the field of interventional cardiology and nanobiotechnologies. The main research direction was an RTD of the multifunctional nanoparticles for theranostics of atherosclerosis. He passed his C.Sc.-doctoral/ graduate degree course in cardiology (A.B.D.) at the Ural State Medical University in 2008-2011. From 2007 to 2009, he worked as a research fellow in some institutions in the Netherlands (UMC St Radboud, Nijmegen; UMCG, Groningen; Erasmus MC, Rotterdam). He is an author of more than 60 articles and grant proposals for the European Commission and has received some national and international awards for his research work. Since Dec 2018 he is a FESC, and Jan 2019 - a FACC, Jan 2020 - a FEACVI.

Publications:
h-index = 10. The publication profile is available in PubMed (akharlamov@orcid), ORCiD (0000-0003-4631-1261), ResearcherID (I-3692-2015), and Scopus (56721449700). The editorial/ reviewer profile (Local editorial board member in EuroIntervention in 2011-2013, member of the International Editorial Board in European Heart Journal in 2013-2015, consulting editor in both Cardiovascular Diagnosis and Therapy in 2013-2017, and International Journal of Nanomedicine in 2013-2019), member of the Editorial Board in World Journal of Cardiology (since 2018) and BMC: Cardiovascular Disorders (since 2020) is available in Publons (publons.com/a/1136995/). We do not collaborate with Facebook and ResearchGate.

Memberships:
European Society of Cardiology - ESC (since 2006; FESC since 2018; FEACVI since 2020), American College of Cardiology - ACC (since 2009; FACC since 2019), American Heart Association - AHA (since 2009), International Society for Stem Cell Research - ISSCR (since 2009), International Society of Nephrology - ISN (since 2009), European Society for Nanomedicine - ESNM (since 2011), The Society for Cardiovascular Angiography and Interventions - SCAI (since 2017), World Sleep Society - WSS (since 2018), The British Society for Nanomedicine - BSN (since 2018), Royal College of Physicians of London - RCP (since 2019), International Society for Cardiovascular Translational Research - ISCTR (since 2019), American Association for the Advancement of Science - AAAS (since 2019), Society of Cardiovascular Computed Tomography - SCCT (since 2019).

Lifetime Achievements

To play, press and hold the enter key. To stop, release the enter key.

press to zoom
press to zoom
press to zoom
press to zoom
press to zoom
press to zoom
press to zoom
press to zoom
press to zoom
press to zoom
press to zoom
press to zoom
press to zoom
press to zoom
press to zoom
press to zoom
press to zoom
press to zoom
IMG_4634.jpg

De Haar Research Task Force (DHRF, DHRF Pro)

Registered in the Netherlands in 2019-2021

with CoC/ KvK: 75124408

Dutch VAT/ BTW: NL002515719B51

 

De Haar Research Foundation

Registered in Estonia in 2022

with registration no.: 16419267

Estonian VAT: EE102453474

 
 

Mapping Twitter followers

Mapping visitors

Visitor counter

Networking.png

Social and Scientific Networking

 GET IN ToUCH! 

CONTACT

US

The Office in the Netherlands:

DHRF

Keurenplein 41

Box G9950

1069CD Amsterdam

The Netherlands

DHRF
Dr Alexander Kharlamov
Strevelsweg 700
T.a.v. Unit 303-G9950
3083AS Rotterdam

The Netherlands

​​

Fax: +31-87-7842273​

akharlamov@dhrfpro.com

  • White LinkedIn Icon
  • White Facebook Icon
  • White Twitter Icon
  • White Instagram Icon

VISIT

US

The Office in Estonia 

De Haar Research Foundation

Hobujaama 4,

Tallinn 10151,

Estonia

Success! Message received.

TELL

US